Maarten Vanhaverbeke

Hi Everyone - 🥸Here are all the 27 late breaking clinical trials presented at @ACCinTouch (ACC.26) with session number, day, time, and objective. 😱See you in NOLA: 👇👇👇

Early results from the TRICURE FIH study show that the Topaz TTVR system achieved complete TR elimination, with all patients reaching none/mild TR at 30 days and 100% device success. A step forward for TTVR in high-risk TR patients. @PatrizioLancel2 @LeopoldOliver86 @Pr_Obadia ; @FedericoAsch ; @juliendreyfus1 #TTVR #StructuralHeart #CardioTwitter

A day in the cathlab: two nice cases at high risk of coronary obstruction during #TAVR: one native, one bioprosthetic valve #YesCCT. Role of TOE #echofirst nicely illustrated. Hartcentrum @az_delta

This high pacemaker rate at discharge underscores a trade-off: the JenaValve’s efficacy in treating high-risk AR patients, where surgical options are limited, comes at the cost of increased conduction disturbances. While AR patients may inherently face higher risk of PM implants (surgical AVR for AR has ~12% PM rates vs. ~7% for AS), the JenaValve’s 24.1% rate warrants further investigation. Future studies should explore whether device design modifications or advanced imaging-guided implantation can mitigate conduction system trauma without compromising valve stability. For now, careful patient selection, particularly avoiding those with baseline RBBB or AV block, and robust pre-procedural risk counseling are critical to balance the benefits of this innovative AR solution against its conduction-related challenges.

🤝 De hartchirurgen van @azsintjan en AZ Delta werken voortaan samen in het West-Vlaams Centrum Hartchirurgie. Zo kunnen we alle mogelijke vormen van hartchirurgie bij volwassenen aanbieden. Minister Frank Vandenbroucke juicht deze samenwerking toe. 👉 bit.ly/409QAH1

COMPARE STEMI ONE is the first RCT to assess 1-month DAPT followed by prasugrel monotherapy in STEMI patients. Also evaluated OCT-guided vs. angiography-guided staged PCI for non-culprit lesions. Protocol published 👇eurointervention.pcronline.com/article/prasug… #DAPT #STEMI #OCT #PCI #rctst @valeriaparadies

DISCOVER THE NEW ISSUE👇 📌Debating the TAVI age limit; 📌A state-of-the-art on the management of complications after valvular interventions; 📌Invasive versus echocardiography-derived gradients after #TAVI; 📌Complex PCI and TAVI; mapping interventional cardiology in Europe; 📌Bioprosthetic failure ten years after TAV-in-SAV; eurointervention.pcronline.com/issue/volume-2… #EAPCI #interventionalcardiology #cardiomed #structuralheartdisease

Now it's getting interesting! After some debate, this might finally be the right population (not too early and not too late) !!! bit.ly/2YrTRILUMINATE #ACC25 @CircAHA @ACCinTouch @escardio @iamritu @mmamas1973 @Hragy @JeunesGACI @A_Trimaille @KardiologieHH

Nice multimodality imaging of a restrictive (type 3) non-calcified severe AR during pre-#TAVR workup #echofirst #YesCCT together with @KDujardin @RAD_AZDELTA and @deltacardio @az_delta Roeselare #Cardiology

Bioprosthetic vs Mechanical #AorticValve Replacement: The debate rages on! 🏥 This new study suggests mechanical may be the way to go for younger patients. Where do you stand? 🤔 🔗 Full #JACC study: jacc.org/doi/10.1016/j.…

🧩 Tricuspid annuloplasty is gaining ground—but is it enough? Discussing the evolving role of annuloplasty devices like the K-Clip and their place in the broader TTVI strategy. Editorial by G. Nickening and J. Vogelhuber: ow.ly/61nU50Vo7V4 #StructuralHeart #TricuspidValve Original article by X. Zhang: ow.ly/NIfw50Vo7V6

Recognize the cute device bouncing in the LAA? Two years after transcatheter mitral paravalvular leak closure — Amplatzer device found embolized to the left atrial appendage. A reminder: closure success is more than the immediate result #CardioTwitter #StructuralHeart @PCRonline

PCR Perspectives: Ole De Backer and Maarten Vanhaverbeke @Mvhave discuss the optimal #TAVI access approach in contemporary practice 📺pcronline.com/Cases-resource… #TAVR #FOAmed

In pts w/ severe #vhdAS & #cvCAD, FFR ≤0.83 & RFR ≤0.85 appear to predict myocardial #ischemia more accurately. 6 months after AVR, FFR 📉, whereas RFR 📈 sig w/ a simultaneous decrease of LV mass & an improvement of microvascular function. jacc.org/doi/10.1016/j.… #JACCINT

I must confess that when I saw the results of the TCW trial at EuroPCR, which, by the way, was presented in a session that didn’t receive much attention, I thought the results were too good to be true. The non-inferiority margin seemed too wide, and I doubted we would see the paper published anytime soon, let alone in a high-impact journal. But here we are – it’s in The Lancet. thelancet.com/journals/lance…

Coronary Physiological Indexes to Evaluate Myocardial Ischemia in Patients With Aortic Stenosis Undergoing Valve Replacement: @JACCJournals 🥸 Do rely on FFR/DFR in AS patients undergoing AVR? 😱 Does AS mask coronary physiology?? 👇👇👇

Sapien 26mm in Acurate neo2 L, low position! Stented portion of Acurate nicely aligning with the Sapien 👍 Excellent result @bostonsci @EdwardsLifesci

Hint: it’s not really an Acurate Neo2 TAVR valve…

Quiz question… Which valve is this? #YesCCT #CardioTwitter @deltacardio @az_delta

#AHA24 Late-breaking trials: Left Atrial Appendage Closure after Ablation for Atrial Fibrillation @Sticchi_Alex provides his take✍️on the results 📊 of the OPTION Trial. 🔗pcronline.com/News/Whats-new… #LAAC #interventionalcardiology #atrialfibrillation #AFib #cardiotwitter